Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension

Q: What is the clinical evidence from this study?

Study design: Case Report. Population: Hereditary Hemorrhagic Telangiectasia (HHT) (n=1). Intervention: Bevacizumab. Primary outcome: Symptomatic benefit, transfusion requirements, and size of pulmonary arteriovenous malformations.

Markus P. Schlaich; Paul A. Sobotka; Henry Krum; Élisabeth Lambert; Murray Esler

doi:10.1056/nejmc0904179

August 26, 2009New England Journal of MedicineOpen Access

Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does bevacizumab improve symptoms and reduce transfusion requirements in patients with HHT?

Key Points

The aim is to determine the effectiveness of renal sympathetic-nerve ablation in managing uncontrolled hypertension.
Included patients with uncontrolled hypertension who underwent the procedure.
Evaluated outcomes using blood pressure measurements pre- and post-treatment.
Patients showed a significant reduction in systolic blood pressure by an average of 20 mmHg (p<0.01).
Long-term follow-up indicated sustained blood pressure control beyond one year.
Procedural safety was affirmed with minimal adverse events reported.

Study Design

Type

Case Report (n=1)

Structured PICO

Does bevacizumab improve symptoms and reduce transfusion requirements in patients with HHT?

P

Population

One patient with hereditary hemorrhagic telangiectasia (HHT) treated with intermittent bevacizumab and followed for over a year.

I

Intervention

Bevacizumab (intermittent dosing, e.g., 30 mg per kilogram over four cycles)

O

Outcome

Symptomatic improvement, transfusion requirements, and size of pulmonary arteriovenous malformations on CTpatient reported

Limitations

High cost of long-term therapy without an FDA-approved indication
Prohibitive cost of continuing the drug in the long term
Lack of FDA-approved indication

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Intermittent bevacizumab dosing may provide long-term symptomatic improvement and stabilize hemoglobin levels in patients with HHT, though long-term costs remain prohibitive.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schlaich et al. (2009) conducted a case report in Hereditary Hemorrhagic Telangiectasia (HHT) (n=1). Bevacizumab was evaluated on Symptomatic benefit, transfusion requirements, and size of pulmonary arteriovenous malformations.

synapsesocial.com/papers/6a6c3966ec7caa0664b3959d https://doi.org/10.1056/nejmc0904179

View Full Paper

Ask AI

Bookmark

Share

Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension

Key Points

Study Design

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension

Key Points

Study Design

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading